Wedbush Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $15.00

Posted by Brian Himes on Aug 14th, 2026

Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price lowered by Wedbush from $16.00 to $15.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

A number of other research firms have also weighed in on RCKT. Chardan Capital reiterated a “buy” rating and set a $11.00 target price on shares of Rocket Pharmaceuticals in a report on Monday, May 11th. Weiss Ratings upgraded Rocket Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Finally, Wall Street Zen lowered Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.57.

Read Our Latest Analysis on Rocket Pharmaceuticals

Rocket Pharmaceuticals Stock Down 2.1%

Shares of NASDAQ RCKT opened at $3.34 on Tuesday. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.08. Rocket Pharmaceuticals has a 52 week low of $2.53 and a 52 week high of $5.45. The firm’s fifty day moving average is $3.37 and its 200 day moving average is $3.61. The company has a market cap of $366.67 million, a price-to-earnings ratio of -19.65 and a beta of 0.47.

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The biotechnology company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.22. During the same quarter in the previous year, the firm posted ($0.62) EPS. On average, equities research analysts expect that Rocket Pharmaceuticals will post -0.88 earnings per share for the current year.

Insiders Place Their Bets

In other Rocket Pharmaceuticals news, COO Christopher James Stevens sold 36,658 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $3.50, for a total transaction of $128,303.00. Following the transaction, the chief operating officer directly owned 505,784 shares of the company’s stock, valued at approximately $1,770,244. The trade was a 6.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Gaurav Shah sold 55,684 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $3.09, for a total transaction of $172,063.56. Following the completion of the transaction, the chief executive officer owned 1,061,724 shares of the company’s stock, valued at $3,280,727.16. This trade represents a 4.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 100,498 shares of company stock worth $327,220. Insiders own 21.30% of the company’s stock.

Institutional Trading of Rocket Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of RCKT. Barclays PLC grew its holdings in shares of Rocket Pharmaceuticals by 2.4% during the 4th quarter. Barclays PLC now owns 153,049 shares of the biotechnology company’s stock worth $537,000 after acquiring an additional 3,656 shares during the period. CANADA LIFE ASSURANCE Co raised its position in shares of Rocket Pharmaceuticals by 94.4% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 5,926 shares in the last quarter. Sanctuary Advisors LLC lifted its stake in shares of Rocket Pharmaceuticals by 63.5% in the 4th quarter. Sanctuary Advisors LLC now owns 17,437 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 6,769 shares during the period. Rice Hall James & Associates LLC lifted its stake in shares of Rocket Pharmaceuticals by 8.1% in the 1st quarter. Rice Hall James & Associates LLC now owns 91,887 shares of the biotechnology company’s stock valued at $329,000 after purchasing an additional 6,900 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in shares of Rocket Pharmaceuticals by 44.0% during the fourth quarter. Quadrant Capital Group LLC now owns 23,096 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 7,056 shares in the last quarter. 98.39% of the stock is currently owned by hedge funds and other institutional investors.

Rocket Pharmaceuticals Company Profile

(Get Free Report)

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.